Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals announced initial efficacy and safety data from a Phase 1b trial of mavorixafor combined with ibrutinib for treating Waldenström’s macroglobulinemia. Key findings show the combination was well tolerated, with a median serum IgM decrease of 51% in patients who completed three treatment cycles. This promising data will be presented as an e-Poster at the European Hematology Association Congress on June 11, 2021. The trial supports further exploration of mavorixafor's role in sensitizing specific genetic mutations to treatment, enhancing therapeutic options for patients with limited responses.
X4 Pharmaceuticals (Nasdaq: XFOR) reported significant clinical advancements in its lead candidate, mavorixafor, targeting rare diseases. The company announced a net loss of $18.7 million for Q1 2021, compared to $11.1 million in Q1 2020. Cash reserves stand at $116.7 million, expected to fund operations into Q4 2022, following a $55 million PIPE financing. The company is set to present initial data from its Phase 1b trial at the EHA Meeting in June 2021 and anticipates an enrollment update for its Phase 3 WHIM trial by mid-2021.
X4 Pharmaceuticals (Nasdaq: XFOR) recently announced the issuance of an inducement award on April 30, 2021, under its 2019 Inducement Equity Incentive Plan. The award includes options to purchase 17,000 shares of common stock at an exercise price of $8.38 per share, reflecting the closing price on the grant date. These options will vest over four years and are aimed at attracting new talent. X4 focuses on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, currently undergoing Phase 3 clinical trials for WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) will report its Q1 2021 financial results on May 6, 2021. A conference call is scheduled for 8:30 a.m. ET, where updates on recent business highlights will also be discussed. The company is focused on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for Waldenström macroglobulinemia and severe congenital neutropenia. Investors can access the call via phone or live webcast on its website.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 2:15 PM ET. The presentation will focus on their innovative therapies targeting the CXCR4 pathway, particularly the lead candidate, mavorixafor, a unique treatment aimed at rare diseases. A live webcast will be available on the company's website, with an archive accessible for 90 days following the event.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on March 31, 2021, that its Board's Compensation Committee granted inducement awards under the 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase a total of 58,000 shares at an exercise price of $8.61 per share, matching the stock's closing price on the grant date. These options will vest over four years, helping attract new employees to the company. X4 focuses on developing therapies targeting diseases related to the CXCR4 pathway, with its lead candidate being mavorixafor.
X4 Pharmaceuticals (Nasdaq: XFOR) announced a private investment in public equity (PIPE) financing, raising approximately $55 million by selling 6,321,837 shares of common stock at $8.70 per share. New and existing institutional investors participated, including Bain Capital Life Sciences and Abingworth. The funds will support the clinical development of X4's lead candidate, mavorixafor, aimed at treating rare diseases. Following the transaction, X4 intends to file a registration statement with the SEC for resale of shares.
X4 Pharmaceuticals (Nasdaq: XFOR) provided a financial update for Q4 and full year 2020, reporting a net loss of $62.1 million, up from $52.8 million in 2019. The company focuses on its lead candidate, mavorixafor, currently undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for Waldenström’s and SCN. X4 expects to complete enrollment in the WHIM trial in 2021, with data expected in 2022. The company also received Fast Track and Rare Pediatric Designations for mavorixafor from the FDA to address unmet needs in WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021. The announcement includes insights into recent business highlights and will be followed by a conference call at 8:30 a.m. ET. The company specializes in therapies targeting the CXCR4 pathway, with its lead candidate mavorixafor undergoing various clinical trials. X4 aims to address rare diseases and those with limited treatment options, leveraging its expertise at its facilities in Boston and Vienna.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will participate in the B. Riley Oncology Institutional Investor Conference on January 20, 2021, at 11:00 AM ET. The event includes a fireside chat and one-on-one investor meetings. Due to audience limitations, advance registration is required. An archived webcast will be available on the X4 Pharmaceuticals website for 90 days post-event. The company focuses on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor currently in Phase 3 and Phase 1b clinical trials for various conditions.